G9pharma co., LTD reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was KRW 3,444.6 million compared to KRW 38,618.94 million a year ago. Basic loss per share from continuing operations was KRW 845 compared to KRW 9,468 a year ago.

Basic loss per share was KRW 845 compared to KRW 9,468 a year ago.